They prevent EGF-A and PCSK9 interaction on LDLR and were included as additional drugs in the standard of care for clinical hypercholesterolemia treatment of patients with evident CVD with or without familial hypercholesterolemia. This evidence concerns the gene LDLR and familial hypercholesterolemia.